XOMA XOMA Royalty Corp

CIK 0000791908 36 ready 8-Ks latest April 27, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 36

Latest filing May 22, 2026, 6:01 AM ET

Top materiality 1.00

Event mix m_and_a ×12 · other_material ×10 · earnings ×9

Sentiment 13 pos · 2 neg · 21 neu

Latest earnings reported 2025-Q3

Recent 8-K filings for XOMA

Highest-materiality recent filing

Ligand to acquire XOMA Royalty for $39.00/share cash plus contingent value rights

April 27, 2026, 7:59 PM ET M&A materiality 1.00 positive item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Per-share consideration: $39.00 cash plus CVRs representing rights to 75% of net proceeds from Janssen litigation.
Support stockholders holding ~47% of shares agree to vote in favor; no financing condition for acquirer.

Read filing →

April 27, 2026, 7:59 PM ET M&A materiality 0.75 neutral item 2.01 item 8.01 item 9.01

XOMA completes Generation Bio acquisition; estimates CVR value at $0.81/share

XOMA paid $4.2913 per share cash plus one non-tradeable CVR for Generation Bio; ~70% of shares tendered.
April 27, 2026, 7:59 PM ET M&A materiality 1.00 positive item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Ligand to acquire XOMA Royalty for $39.00/share cash plus contingent value rights

Per-share consideration: $39.00 cash plus CVRs representing rights to 75% of net proceeds from Janssen litigation.
March 18, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

XOMA Royalty reports 2025 net income $31.7M vs loss $13.8M; royalties up 68% YoY

Full-year cash receipts $50.5M ($33.6M royalties, +68% YoY; $16.9M milestones); Q4 net income $6.1M vs loss $4.0M YoY.
February 9, 2026, 6:59 PM ET M&A materiality 0.75 neutral item 2.01 item 8.01 item 9.01 ◈ M&A Transactions

XOMA Royalty closes acquisition of Generation Bio for $4.2913/share plus CVR

Completed tender offer; 4,722,533 shares (approx. 70%) tendered, all accepted.
February 2, 2026, 6:59 PM ET M&A materiality 0.65 neutral item 2.01 item 8.01 item 9.01 ◈ M&A Transactions

XOMA completes acquisition of LAVA legacy assets; details Pfizer, Janssen programs and CVR terms

XOMA completed acquisition of LAVA legacy assets (EGFRd2, JNJ-89853413, LAVA-1266) on Nov 20, 2025.
January 15, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01

XOMA Royalty names Jeffrey Trigilio CFO; Thomas Burns departs after ~19 years

Thomas Burns stepped down as CFO effective Jan 12, 2026; separation agreement includes $16k/month consulting for 3 months.
December 5, 2025, 6:59 PM ET M&A materiality 0.70 neutral item 2.01 item 8.01 item 9.01

XOMA Royalty completes acquisition of Mural Oncology for $2.035/share

Deal closed Dec 5, 2025; Mural shareholders received $2.035 cash per share.
November 21, 2025, 6:59 PM ET M&A materiality 0.60 neutral item 2.01 item 8.01 item 9.01 ◈ M&A Transactions

XOMA completes acquisition of LAVA Therapeutics for $1.04/share plus CVRs

Subsequent Offering Period expired Nov 20, 2025; Post-Offer Reorganization effective same day.
November 12, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

XOMA Royalty Q3 net income $14.1M vs loss $17.2M; revenue $9.4M; cash receipts $43.9M YTD

Net income of $14.1M in Q3 2025, compared to net loss of $17.2M in Q3 2024.
October 3, 2025, 7:59 PM ET other materiality 0.65 neutral item 1.01 item 9.01

XOMA enters ATM sales agreements for up to $125M in common stock and preferred depositary shares

Up to $75M common stock ATM with Leerink Partners; 3% commission.
September 23, 2025, 7:59 PM ET M&A materiality 0.75 neutral item 2.01 item 8.01 item 9.01

XOMA completes acquisition of HilleVax for $1.95 per share plus CVR

XOMA acquired HilleVax via tender offer and merger; offer price of $1.95 cash plus one CVR per share.
August 15, 2025, 7:59 PM ET M&A materiality 0.60 neutral item 2.01 item 8.01 item 9.01 ◈ M&A Transactions

XOMA completes acquisition of Turnstone Biologics for $0.34 cash plus CVR per share

XOMA accepted 17,192,002 shares (~74% of outstanding) at $0.34 plus one CVR per share.
August 13, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

XOMA Royalty Q2 net income $9.2M; acquires Turnstone, HilleVax, LAVA; H1 cash receipts $29.6M

Net income $9.2M (Q2 2025) vs $16.0M (Q2 2024); income & revenue $13.1M vs $11.1M.
May 13, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

XOMA Royalty Q1 net income $2.4M, total revenues $15.9M; adds Castle Creek royalty, sells Kinnate assets

Q1 2025 total revenues $15.9M (vs $1.5M Q1 2024); net income $2.4M (vs net loss $8.6M).
March 17, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

XOMA Royalty reports Q4/FY2024 revenue $28.5M, net loss $13.8M; portfolio doubled to 120+ assets

Total revenue $8.7M Q4, $28.5M FY2024 (vs $1.8M and $4.8M in 2023); net loss $4.0M Q4, $13.8M FY2024.
February 11, 2025, 6:59 PM ET M&A materiality 0.75 neutral item 9.01

XOMA files Pulmokine financials for $20M cash acquisition closed Nov 26, 2024

XOMA acquired Pulmokine for $20M cash at closing; historical audited and unaudited financials filed.
December 2, 2024, 6:59 PM ET M&A materiality 0.75 positive item 8.01 item 9.01

XOMA Royalty acquires Pulmokine for $20M, adding seralutinib royalty/milestone interest

Acquisition of Pulmokine for $20M cash at closing plus success-based consideration.
November 7, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

XOMA Q3: Revenue $7.2M, net loss $17.2M ($14M impairment); Twist 50% interest acquired

Total income/revenue of $7.2M in Q3 2024 vs $0.8M in Q3 2023; cash receipts $9.9M.
October 22, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

XOMA Royalty acquires 50% of Twist Bioscience's royalty/milestone economics for $15M

Acquired 50% economic interest in milestones/royalties from Twist's 60+ early-stage programs across 30 partners for $15M upfront.
August 13, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

XOMA Royalty Q2 net income $16.0M; receives $22.6M cash; acquires Kinnate and Daré rights; posts $9.0M impairment

Net income $16.0M vs net loss $5.4M in Q2 2023; total income/revenue $11.1M; cash receipts $22.6M.
June 13, 2024, 7:59 PM ET M&A materiality 0.80 negative item 9.01

XOMA closes Kinnate acquisition for $122.7M cash; Q1 2024 pro forma net loss $21.7M

Cash consideration of $2.5879 per share + one CVR; aggregate cash $122.7M financed from cash on hand.
May 9, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

XOMA Q1 net loss $8.6M; FDA approves OJEMDA triggering $9M milestone

Q1 revenue $1.5M (vs $0.4M YoY) on $1M AVEO milestone; net loss $8.6M (vs $9.8M YoY).
April 30, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

XOMA pays $22M upfront for royalty interests in three women's health assets from Daré Bioscience

XOMA paid $22M cash to Daré for royalties on XACIATO, Ovaprene, and Sildenafil Cream.
April 25, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

XOMA earns $9M milestone on FDA approval of Day One's OJEMDA for pediatric low-grade glioma

XOMA earned $9M milestone from FDA accelerated approval of Day One's OJEMDA (tovorafenib) for relapsed/refractory BRAF-altered pLGG.
April 3, 2024, 7:59 PM ET M&A materiality 0.90 neutral item 2.01 item 8.01 item 9.01 ◈ M&A Transactions

XOMA completes acquisition of Kinnate Biopharma for $2.5879 per share plus CVRs

XOMA purchased ~81% of Kinnate shares via tender offer at $2.5879/share plus one CVR per share.
March 8, 2024, 6:59 PM ET earnings materiality 0.85 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

XOMA reports Q4 2023 net loss $20.1M, revenue $1.8M; cash $159.6M

Full year 2023 net loss $40.8M vs $17.1M in 2022; revenue $4.8M vs $6.0M.

Earnings & guidance

2025-Q3 EPS reported $1.20 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.70 · Most common event m_and_a

13 positive 2 negative 21 neutral

source · XOMA on sec.gov